rituximab

Summary

Summary: A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.

Top Publications

  1. Jaime Perez J, Rodríguez Romo L, Gonzalez Llano O, Chapa Rodríguez A, Gomez Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol. 2009;144:794-5 pubmed publisher
  2. Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni P, Gerloni V. Rituximab for uveitis. Ophthalmology. 2011;118:223-4 pubmed publisher
  3. Bitik B, Gonul I, Haznedaroglu S, Goker B, Tufan A. Granulomatous interstitial nephritis associated with Primary Sjögren's syndrome. Z Rheumatol. 2017;76:458-460 pubmed publisher
    ..we report on a patient who was concurrently diagnosed with pSS and GIN and was treated successfully with rituximab (RTX)...
  4. Camacho X, Machado C, Garcia M, Gambini J, Banchero A, Fernandez M, et al. Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma. Oncology. 2017;92:229-242 pubmed publisher
    b>Rituximab was the first monoclonal antibody approved for the treatment of B-cell non-Hodgkin lymphoma (NHL) expressing CD20 antigen...
  5. Robier C, Neubauer M, Reicht G. Marked elevation of procalcitonin in a patient with a drug related infusion reaction to rituximab. Clin Chem Lab Med. 2016;54:e101-3 pubmed publisher
  6. Md Yusof M, Kabia A, Darby M, Lettieri G, Beirne P, Vital E, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford). 2017;56:1348-1357 pubmed publisher
    To evaluate the effect of rituximab (RTX) in patients with RA-related interstitial lung disease (RA-ILD) and identify factors associated with outcome after treatment...
  7. Mochizuki H, Kato M, Higuchi T, Koyamada R, Arai S, Okada S, et al. Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions. Intern Med. 2017;56:1095-1099 pubmed publisher
    ..The patient was diagnosed with IgG4-related disease (RD). Rituximab only had a slight effect...
  8. Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials?. Blood. 2017;130:581-589 pubmed publisher
    ..b>Rituximab (RTX) is frequently considered as its "ancestor" and OBZ clinical development was justified by the ..
  9. Miyakawa Y. TTP and aHUS: new insights. Rinsho Ketsueki. 2017;58:530-536 pubmed publisher
    ..Unfortunately, most professionals in the fields of hematology/oncology are unaware of these diseases. Therefore, I will provide an updated overview of TTP and aHUS in this article. ..

More Information

Publications62

  1. Zhang L, Ghielmini M, Cheson B, Ujjani C. Pros and cons of rituximab maintenance in follicular lymphoma. Cancer Treat Rev. 2017;58:34-40 pubmed publisher
    ..Most patients present with advanced disease and are incurable with current therapy. The approval of rituximab has revolutionized the treatment of follicular lymphoma when administered in the induction setting for high-..
  2. Ignatova T, Kozlovskaya L, Gordovskaya N, Chernova O, Milovanova S, Novikov P, et al. [Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment]. Ter Arkh. 2017;89:46-52 pubmed publisher
    ..8±3.6 years. The efficiency of traditional (corticosteroids ± cyclophosphamide) and selective (rituximab) immunosuppressive therapy (IST) was estimated in 31 and 15 observations, respectively, and that of antiviral ..
  3. Carson K, Bennett C. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma. 2009;50:323-4 pubmed publisher
  4. Hehir M, Hobson Webb L, Benatar M, Barnett C, Silvestri N, Howard J, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology. 2017;89:1069-1077 pubmed publisher
    To evaluate the efficacy of rituximab in treatment of anti-muscle-specific kinase (MuSK) myasthenia gravis (MG)...
  5. Ney D, Abrey L. Maintenance therapy for central nervous system lymphoma with rituximab. Leuk Lymphoma. 2009;50:1548-51 pubmed publisher
  6. Jiang L, Liu Y, Zhang L, Santoro C, Rodriguez A. Rituximab for treating inhibitors in people with inherited severe hemophilia. Cochrane Database Syst Rev. 2017;7:CD010810 pubmed publisher
    ..Given the wide 'off-label' use of rituximab for treating people with hemophilia and inhibitors, its efficacy and safety need to be evaluated...
  7. Bagdure S, Fisher M, Ryan M, Khasawneh F. Rhodococcus erythropolis encephalitis in patient receiving rituximab. Emerg Infect Dis. 2012;18:1377-9 pubmed publisher
  8. Périer A, Savey L, Marcelin A, Serve P, Saadoun D, Barete S. De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases. Arthritis Rheumatol. 2017;69:2241-2246 pubmed publisher
    ..b>Rituximab (RTX) is currently used for the treatment of several autoimmune or inflammatory diseases and humoral organ ..
  9. Hay S, Burchett S, Odejide O, Cataltepe S. Septic Episodes in a Premature Infant After In Utero Exposure to Rituximab. Pediatrics. 2017;140: pubmed publisher
    b>Rituximab is an increasingly used immunotherapeutic agent for women of reproductive age for treatment of autoimmune diseases, leukemias, and lymphomas...
  10. Martin P, Storer B, Inamoto Y, Flowers M, Carpenter P, Pidala J, et al. An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood. 2017;130:360-367 pubmed publisher
    ..This prospective observational study was registered at www.clinicaltrials.gov as #NCT00637689. ..
  11. Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, et al. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017;130:1628-1638 pubmed publisher
    ..that HDAC6 inhibition augments in vitro efficacy of anti-CD20 mAbs and improves survival of mice treated with rituximab. Mechanistically, we demonstrate that HDAC6 influences synthesis of CD20 protein independently of the regulation ..
  12. Samani A, Davagnanam I, Cockerell O, Ramsay A, Patani R, Chataway J. Lymphomatosis cerebri: a treatable cause of rapidly progressive dementia. J Neurol Neurosurg Psychiatry. 2015;86:238-40 pubmed publisher
  13. Rider L, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman B, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology . Arthritis Rheumatol. 2017;69:911-923 pubmed publisher
    ..data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial...
  14. Lutt J, Pisculli M, Weinblatt M, Deodhar A, Winthrop K. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol. 2008;35:1683-5 pubmed
  15. Nabhan C, Mato A, Flowers C, Grinblatt D, Lamanna N, Weiss M, et al. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 2017;17:198 pubmed publisher
    ..E-CLL patients were more likely to receive rituximab monotherapy (19.3 vs. 8.6%; p < 0.0001) and chemotherapy-alone regimens (p < 0...
  16. Sawas A, Farber C, Schreeder M, Khalil M, Mahadevan D, Deng C, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017;177:243-253 pubmed publisher
    ..activity of ublituximab, a unique type I, chimeric, glycoengineered anti-CD20 monoclonal antibody, in rituximab-relapsed or -refractory patients with B-cell non-Hodgkin lymphoma (B-NHL) or chronic lymphocytic leukaemia (CLL)...
  17. Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, et al. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Br J Haematol. 2017;179:410-420 pubmed publisher
    ..We investigated higher rituximab doses for elderly male DLBCL patients...
  18. Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, et al. Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017;187:213-219.e2 pubmed publisher
    To evaluate the efficacy and safety of rituximab for treating pediatric systemic lupus erythematosus (pSLE). We performed a systematic review to evaluate the efficacy and safety of rituximab in children with pSLE...
  19. Adem J, Eray M, Eeva J, Nuutinen U, Pelkonen J. Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas. Mol Immunol. 2017;88:135-137 pubmed publisher
    ..For instance, repeated rituximab (anti-CD20 antibody) treatment may lead to the loss of its target cell surface molecule, CD20...
  20. Reddy N, Greer J, Morgan D, Chen H, Park S, Richards K. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. Leukemia. 2017;31:241-244 pubmed publisher
  21. Clatworthy M, Watson C, Plotnek G, Bardsley V, Chaudhry A, Bradley J, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360:2683-5 pubmed publisher
  22. Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72:308-10 pubmed publisher
  23. Moerman R, Arends S, Meiners P, Brouwer E, Spijkervet F, Kroese F, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73:472-4 pubmed publisher
  24. Hershberg U, Meng W, Zhang B, Haff N, St Clair E, Cohen P, et al. Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome. Arthritis Res Ther. 2014;16:R51 pubmed publisher
    ..Therapy with anti-CD20 (rituximab) has the potential to eliminate expanded B-cell clones and thereby potentially ameliorate disease...
  25. Gagez A, Tuaillon E, Cezar R, Dartigeas C, Mahe B, Letestu R, et al. Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and Fc?RIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups. Blood Cancer J. 2016;6:e389 pubmed publisher
  26. Perera M, Suarez A, Luzardo H, Lopez J, Molero T. Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia. Ann Hematol. 2012;91:1497-8 pubmed publisher
  27. Yin H, Meng T, Shu L, Mao M, Zhou L, Chen H, et al. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma. Chem Biol Drug Des. 2017;90:892-899 pubmed publisher
    In this study, a novel reduction-sensitive drug delivery system, the rituximab-doxorubicin (RTX-DOX) micellar nanoparticle (RDMN), was specially designed for targeted delivery and release of DOX in non-Hodgkin's lymphoma (NHL) cells...
  28. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377:1331-1344 pubmed publisher
    b>Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody...
  29. Strüßmann T, Fritsch K, Baumgarten A, Fietz T, Engelhardt M, Mertelsmann R, et al. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. Br J Haematol. 2017;178:927-935 pubmed publisher
    ..To optimize outcome, two approaches were carried out: Cohort 1 patients received four cycles R-CHOP-21 (rituximab, cyclophosphamide, daunorubicin, vincristine, prednisolone over 21 days) followed by first-line high-dose ..
  30. Tagami M, Nagai T, Sekimukai D, Hara R, Azumi A. Uveal extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type with concomitant extraocular lesions in a Japanese man. Jpn J Ophthalmol. 2011;55:585-587 pubmed publisher
  31. Boyle T, Connors J, Gascoyne R, Berry B, Sehn L, Bashash M, et al. Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases. Br J Haematol. 2017;178:442-447 pubmed publisher
    ..NHL-specific survival results were similar. ..
  32. Chamberlain N, Massad C, Oe T, Cantaert T, Herold K, Meffre E. Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest. 2016;126:282-7 pubmed publisher
    ..Treatment with rituximab, an anti-CD20 mAb that depletes B cells, has been shown to preserve ? cell function in T1D patients and improve ..
  33. Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310:1664 pubmed publisher
  34. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946-965 pubmed publisher
    ..For physically fit patients, chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab remains the current standard therapy...
  35. Kim S, Huh S, Lee S, Joung A, Kim H. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110-7 pubmed
    A previous 2-year analysis of repeated rituximab treatment in patients with neuromyelitis optica (NMO) revealed significant improvements in relapse rates and disability...
  36. Mecchella J, Rigby W, Zbehlik A. Pancytopenia and cough in a man with amyopathic dermatomyositis. Arthritis Care Res (Hoboken). 2014;66:1587-90 pubmed publisher
  37. Abou Zahr A, Bose P, Keating M. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother. 2017;18:857-873 pubmed publisher
    ..Additionally, new and more potent monoclonal antibodies against CD20 have replaced/may replace rituximab in many settings...
  38. Chao M, Hong J, Kunder C, Lester L, Schrier S, Majeti R. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. Am J Hematol. 2015;90:78-81 pubmed publisher
  39. Berentsen S, Randen U, Oksman M, Birgens H, Tvedt T, Dalgaard J, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130:537-541 pubmed publisher
    ..b>Rituximab monotherapy and fludarabine-rituximab in combination are documented treatment options...
  40. Kantarjian H, Schiffer C, Burnett A. Hematologic malignancies: where do we stand in 2011?. J Clin Oncol. 2011;29:473-4 pubmed publisher
  41. Adler N, Sia C, Polchleb C, Jane S, Aung A. Intravascular large B cell lymphoma with haemophagocytic syndrome: a double lethal masquerade. Intern Med J. 2015;45:1310-2 pubmed publisher
  42. Palma E, González V, Grünholz D, Landaeta M, Mallea M, Perez J, et al. [Shock as an adverse reaction to rituximab: Case report]. Rev Med Chil. 2017;145:260-263 pubmed publisher
    b>Rituximab is a plausible alternative first-line treatment of ANCA-associated vasculitis. Adverse effects related to its infusion are common and usually have a benign course...
  43. Jones J, Shyu I, Newkirk M, Rigby W. A rheumatoid factor paradox: inhibition of rituximab effector function. Arthritis Res Ther. 2013;15:R20 pubmed publisher
    b>Rituximab (RTX) therapy of rheumatoid arthritis (RA) exhibits enhanced effectiveness in seropositive patients...
  44. Skopelja Gardner S, Jones J, Hamilton B, Danilov A, Rigby W. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells. J Immunol. 2017;199:1275-1282 pubmed publisher
    b>Rituximab (RTX) has been the hallmark anti-CD20 mAb for the treatment of B cell neoplasms, including B cell chronic lymphocytic leukemia (B-CLL)...
  45. Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med. 2012;366:1165-6 pubmed publisher
  46. Wolfromm A, Delarue R. [Lymphomas: A therapeutic update]. Rev Med Interne. 2017;38:685-690 pubmed publisher
    ..Immunotherapy with monoclonal antibodies entered the market with rituximab in diffuse large B-cell lymphomas, in the 1990s and it is now developing as new-generation anti-CD20 antibodies (..
  47. Narayan N, Owen D, Taylor P. Advances in positron emission tomography for the imaging of rheumatoid arthritis. Rheumatology (Oxford). 2017;56:1837-1846 pubmed publisher
    ..We also highlight potentially important preclinical studies of PET in arthritis and discuss current limitations of PET as well as ongoing developments in PET technology likely to be of benefit for arthritis imaging. ..
  48. Knight A, Hallenberg H, Baecklund E. Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series. Clin Rheumatol. 2014;33:841-8 pubmed
    The objective of this work was to study the efficacy and safety of pre-emptive rituximab (RTX) in a series of patients with severe relapsing granulomatosis with polyangiitis (GPA)...
  49. Zou D, Yi S, Cui R, Liu W, Li C, Zhong S, et al. BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase. BMC Med Genet. 2017;18:16 pubmed publisher
    ..BCL2 and MYC rearrangements were the sole independent factor correlated with CNSI. It is possible that both BCL2 and MYC gene aberrations may contribute to the high incidence of CNSI observed in leukemic phase of patients with DLBCL. ..
  50. Tomiyama Y. Current topics in primary immune thrombocytopenia. Rinsho Ketsueki. 2017;58:537-541 pubmed publisher
    ..In this chapter, the recent topics regarding the diagnosis and management of ITP have been reviewed. ..
  51. Giaime P, Daniel L, Burtey S. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy. Clin Nephrol. 2015;83:57-60 pubmed publisher
    ..C3Nef was present. We treated him with rituximab as the sole immunosuppressive regimen and obtained a complete remission on proteinuria...
  52. Ducassou S, Leverger G, Fernandes H, Chambost H, Bertrand Y, Armari Alla C, et al. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. Br J Haematol. 2017;177:751-758 pubmed publisher
    ..It appears that rituximab is indicated in such circumstances...
  53. Jin J. High-dose methylprednisolone is effective in treating radiation-induced refractory haemorrhagic cystitis. Intern Med J. 2014;44:615-7 pubmed publisher